SCHEMBL6585196

SCHEMBL6585196

O=C(O)c1ccc(-c2nn(-c3ccccc3)cc2NS(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.54
KDM4E B2RXH2 7/20 0.54
LMNA P02545 6/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
MEN1 O00255 9/20 0.52
KMT2A Q03164 9/20 0.52
ALDH1A1 P00352 5/20 0.52
HPGD P15428 1/20 0.52
PTGES O14684 2/20 0.51
ALOX5 P09917 2/20 0.51
HTT P42858 4/20 0.50
RAB9A P51151 3/20 0.50
POLB P06746 1/20 0.50
KEAP1 Q14145 1/20 0.50
NFE2L2 Q16236 1/20 0.50
MITF O75030 1/20 0.49
XBP1 P17861 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6580398 0.89 MAPT (0.54) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL7505481 0.75 MAPT (0.54) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL6585190 0.71 GRM5 (0.54) MAPTLMNASMN1; SMN2ALDH1A1CYP2C9
SCHEMBL16510709 0.70 ALDH1A1 (0.65) MAPTKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL27660231 0.69 KEAP1 (0.76) MAPTMEN1KMT2AHPGDKEAP1
SCHEMBL14175673 0.69 MEN1 (0.57) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL893905 0.68 CA12 (0.73) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL23928668 0.68 CA12 (0.80) MAPTKDM4ELMNASMN1; SMN2MEN1
SCHEMBL3050268 0.67 MCOLN3 (0.68) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL19652416 0.67 PTGS2 (0.76) MAPTKDM4ELMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1257539-B1 AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS ORTHO MCNEIL PHARM INC (US) 2004-12-29 EP disclosed
US-6531478-B2 For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders KORDIK CHERYL P (US) 2003-03-11 US disclosed
US-20020065289-A1 Amino pyrazole derivatives useful for the treatment of obesity and other disorders KORDIK CHERYL P (US) 2002-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065289-A1 Amino pyrazole derivatives useful for the treatment of obesity and other disorders NPY5R, NPY1R, NPY4R MAPT 2451/4885KDM4E 2084/4885LMNA 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.